Literature DB >> 7638236

Disruption of cellular signaling pathways by daunomycin through destabilization of nonlamellar membrane structures.

P V Escribá1, M Sastre, J A García-Sevilla.   

Abstract

Albeit anthracyclines are widely used in the treatment of solid tumors and leukemias, their mechanism of action has not been elucidated. The present study gives relevant information about the role of nonlamellar membrane structures in signaling pathways, which could explain how anthracyclines can exert their cytocidal action without entering the cell [Tritton, T. R. & Yee, G. (1982) Science 217, 248-250]. The anthracycline daunomycin reduced the formation of the nonlamellar hexagonal (HII) phase (i.e., the hexagonal phase propensity), stabilizing the bilayer structure of the plasma membrane by a direct interaction with membrane phospholipids. As a consequence, various cellular events involved in signal transduction, such as membrane fusion and membrane association of peripheral proteins [e.g., guanine nucleotide-binding regulatory proteins (G proteins and protein kinase C-alpha beta)], where nonlamellar structures (negative intrinsic monolayer curvature strain) are required, were altered by the presence of daunomycin. Functionally, daunomycin also impaired the expression of the high-affinity state of a G protein-coupled receptor (ternary complex for the alpha 2-adrenergic receptor) due to G-protein dissociation from the plasma membrane. In vivo, daunomycin also decreased the levels of membrane-associated G proteins and protein kinase C-alpha beta in the heart. The occurrence of such nonlamellar structures favors the association of these peripheral proteins with the plasma membrane and prevents daunomycin-induced dissociation. These results reveal an important role of the lipid component of the cell membrane in signal transduction and its alteration by anthracyclines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638236      PMCID: PMC41386          DOI: 10.1073/pnas.92.16.7595

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Heterogeneity of radioligand binding to alpha-adrenergic receptors. Analysis of guanine nucleotide regulation of agonist binding in relation to receptor subtypes.

Authors:  B B Hoffman; D Mullikin-Kilpatrick; R J Lefkowitz
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

2.  Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation.

Authors:  G H Lyman; H D Preisler; D Papahadjopoulos
Journal:  Nature       Date:  1976-07-29       Impact factor: 49.962

3.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

4.  The anticancer agent adriamycin can be actively cytotoxic without entering cells.

Authors:  T R Triton; G Yee
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

5.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

Authors:  A De Lean; J M Stadel; R J Lefkowitz
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

6.  Differential regulation of the alpha 2-adrenergic receptor by Na+ and guanine nucleotides.

Authors:  T Michel; B B Hoffman; R J Lefkowitz
Journal:  Nature       Date:  1980-12-25       Impact factor: 49.962

7.  Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains.

Authors:  A Miralles; G Olmos; M Sastre; F Barturen; I Martin; J A Garcia-Sevilla
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

8.  Alpha 2-adrenoceptor subtypes identified by [3H]RX821002 binding in the human brain: the agonist guanoxabenz does not discriminate different forms of the predominant alpha 2A subtype.

Authors:  M Sastre; J A García-Sevilla
Journal:  J Neurochem       Date:  1994-09       Impact factor: 5.372

9.  N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.

Authors:  M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

10.  Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential.

Authors:  A Arcangeli; M Carlà; M R Del Bene; A Becchetti; E Wanke; M Olivotto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more
  24 in total

1.  Role of lipid polymorphism in G protein-membrane interactions: nonlamellar-prone phospholipids and peripheral protein binding to membranes.

Authors:  P V Escribá; A Ozaita; C Ribas; A Miralles; E Fodor; T Farkas; J A García-Sevilla
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Triacylglycerol mimetics regulate membrane interactions of glycogen branching enzyme: implications for therapy.

Authors:  Rafael Alvarez; Jesús Casas; David J López; Maitane Ibarguren; Ariadna Suari-Rivera; Silvia Terés; Francisca Guardiola-Serrano; Alexander Lossos; Xavier Busquets; Or Kakhlon; Pablo V Escribá
Journal:  J Lipid Res       Date:  2017-06-19       Impact factor: 5.922

Review 3.  Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

4.  Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy.

Authors:  Gwendolyn Barceló-Coblijn; Maria Laura Martin; Rodrigo F M de Almeida; Maria Antònia Noguera-Salvà; Amaia Marcilla-Etxenike; Francisca Guardiola-Serrano; Anja Lüth; Burhard Kleuser; John E Halver; Pablo V Escribá
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

5.  Parallel modulation of receptor for activated C kinase 1 and protein kinase C-alpha and beta isoforms in brains of morphine-treated rats.

Authors:  P V Escribá; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid.

Authors:  Victoria Lladó; Silvia Terés; Mónica Higuera; Rafael Alvarez; Maria Antònia Noguera-Salva; John E Halver; Pablo V Escribá; Xavier Busquets
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

7.  Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: relationship with non-adrenoceptor [3H]-idazoxan binding sites.

Authors:  P V Escribá; R Alemany; M Sastre; G Olmos; A Ozaita; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity.

Authors:  Ana Catarina Alves; Daniela Ribeiro; Miguel Horta; José L F C Lima; Cláudia Nunes; Salette Reis
Journal:  J R Soc Interface       Date:  2017-08       Impact factor: 4.118

9.  Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Authors:  Jon M Appel; Benny V Jensen; Dorte L Nielsen; Marianne Ryberg; Bo Zerahn
Journal:  Int J Cardiovasc Imaging       Date:  2009-10-13       Impact factor: 2.357

10.  Inhibition of Bacterial Toxin Activity by the Nuclear Stain, DRAQ5™.

Authors:  Joshua N Webb; Evan Koufos; Angela C Brown
Journal:  J Membr Biol       Date:  2016-04-02       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.